- Bloomberg•5 hours ago
Neither Bloomberg's M&A executive editor Jeff McCracken nor host Alex Sherman can remember a deal quite like Johnson & Johnson's pursuit of Swiss drugmaker Actelion. First J&J publicly stated it was in ...
- Forbes•16 hours ago
There are nearly 1,300 dividend-paying companies that offer the opportunity to buy shares directly through their DRIP. Many of them do not charge commissions or fees.
- Motley Fool•18 hours ago
Remicade, Xarelto, Imbruvica, Darzalex, and Stelara could have the biggest impact on Johnson & Johnson's top and bottom lines in 2017.
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||114.37 - 114.90|
|52 Week Range||94.28 - 126.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.11|
|Dividend & Yield||3.20 (2.79%)|
|1y Target Est||N/A|